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Abstract
Peppermint oil (PMO) is effective in the treatment of functional abdominal pain
disorders, but its mechanism of action is unclear. Evidence suggests PMO has microbicidal activity. We investigated the effect of three different doses of PMO on
gut microbiome composition. Thirty children (7–12 years of age) with functional
abdominal pain provided a baseline stool sample prior to randomization to 180,
360, or 540 mg of enteric coated PMO (10 participants per dose). They took their
respective dose of PMO (180 mg once, 180 mg twice, or 180 mg thrice daily) for
1 week, after which the stool collection was repeated. Baseline and post-PMO
stools were analyzed for microbiome composition. There was no difference in
alpha diversity of the gut microbiome between the baseline and post-PMO treatment. Principal coordinate analysis revealed no significant difference in overall
bacterial composition between baseline and post-PMO samples, as well as between the PMO dose groups. However, the very low abundant Collinsella genus
and three operational taxonomic units (one belonging to Collinsella) were significantly different in samples before and after PMO treatment. The Firmicutes/
Bacteroidetes ratio was lower in children who received 540 mg of PMO compared
to the 180 mg and 360 mg dose groups (p = 0.04). Network analysis revealed
separation between pre- and post-PMO fecal samples with the genus Collinsella
driving the post-PMO clusters. PMO administration appeared to impact only
low abundance bacteria. The 540 mg PMO dose differentially impacted the
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Firmicutes/Bacteroidetes ratio. A higher dose and/or longer duration of treatment might yield different results.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Peppermint oil (PMO) is used commonly to treat gut disorders. In vitro PMO can
be bactericidal.
WHAT QUESTION DID THIS STUDY ADDRESS?
Does oral administration of PMO impact gut microbiome composition? Is there a
dose-response impact on gut microbiome composition?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
PMO at the doses tested can impact gut microbiome composition. The highest
dose of PMO (540 mg) changed the Firmicutes/Bacteroidetes ratio.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR
TRANSLATIONAL SCIENCE?
Some of the clinical benefit of PMO may be mediated through a change in gut
microbiome composition. Higher doses and/or longer treatment should be tested
to evaluate the impact on gut microbiome composition.

I N T RO DU CT ION

MATERIALS AND METHODS

Mint plants have been used for thousands of years as medicinals.1 Peppermint oil (PMO) is obtained by steam distillation from peppermint leaves. PMO is commonly used
to treat functional gastrointestinal conditions, such as irritable bowel syndrome and dyspepsia.2–6 The majority of
evidence suggests that PMO is effective in the treatment
of irritable bowel syndrome.2,4,5,7 How PMO exerts its beneficial effect is less clear; generally, it has been ascribed
to its ability to act as an antispasmodic.7 However, PMO,
like several other essential oils, also has been shown to
have antimicrobial, antifungal, and even antiviral effects;
however, these studies have been carried out primarily in
vitro or in rodents.7–9
In a recent study, we investigated the effect of three different doses of PMO (180, 360, and 540 mg) on its pharmacokinetics in children.10 Given the use of PMO to treat
functional gastrointestinal conditions, we carried out the
study in children with functional abdominal pain.10 The
doses studied were based on our previous pilot trial of
PMO in children.11 As part of that dose ranging study,10
stools were collected to investigate the effect of PMO on
the gut microbiome composition in the children, with
the primary outcome being the detection of a significant
change in gut microbiome composition. Studying a dose
range allowed us also to investigate the microbiome response to different doses of PMO. We hypothesized that
PMO would impact gut microbiome composition and that
there would be a dose-response impact on gut microbiome
composition.

Participants
Children 7–12 years of age with functional abdominal
pain, as defined by pediatric Rome III criteria, were recruited from primary and tertiary (pediatric gastroenterology) care within the Texas Children’s Hospital healthcare
network based in Houston, Texas, USA, which is the largest pediatric provider in the area.12 Children with functional abdominal pain were studied (as opposed to those
with irritable bowel syndrome) based on the request
from the funding agency. Informed consent was obtained
from parents and assent was obtained from children. The
study was approved by the Baylor College of Medicine
Institutional Review Board. The study was registered at
www.clinicaltrials.gov (NCT03295747).
Medical records were screened by trained research
coordinators for International Classification of Disease-
10th edition (ICD-10) codes for abdominal pain and functional abdominal pain. Secondary review of medical and
laboratory records was performed by a pediatric gastroenterologist (author R.J.S.). Participants were screened
via telephone and initially classified as having functional
abdominal pain using a modified pediatric Rome III
questionnaire.12,13
Children were excluded if screening or review revealed a significant chronic medical condition (e.g.,
celiac disease and cystic fibrosis), chronic vomiting,
unexplained weight loss, hematochezia, gastrointestinal (GI) tract surgery, significant developmental delay,
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an organic GI disorder, or other comorbidity that could
have affected study results. In addition, use of antibiotics, probiotics, PMO-containing products, or gastric acid
modifying medication within the prior month was an
exclusion. Women having reached menarche also were
excluded in order to study a more developmentally homogeneous group.
During the baseline (prior to PMO) period, participants who passed screening maintained daily validated
pain and stooling diaries for 2 weeks.14,15 Children self-
reported the number and severity of pain episodes on a
0–10 scale with 10 being the most severe.14 The number
and type of stools passed per day was recorded using the
Bristol Stool Scale.15 Children also completed the Rome
III Diagnostic Questionnaire for Pediatric Functional GI
Disorders. Confirmation of the diagnosis of functional
abdominal pain was based on evaluation of the pain and
stool diaries.13

Study design
The decision to study 10 participants per dose was based
on the results of our pilot study.11 Participants were instructed to continue their usual diet during the baseline
period and during administration of PMO.
Prior to administration of PMO, children collected
a stool sample at home using a self-sealing container
which then was kept frozen and delivered to our laboratory via courier along with the pain and stool diary.
Participants subsequently came to the Children’s
Nutrition Research Center and were randomized (www.
randomizer.org) to receive one of three doses of PMO
(Pepogest; Nature’s Way Products, LLC, Lehi, UT): 180,
360, or 540 mg. A pharmacist provided the PMO to the
investigators based on the results of the randomization
scheme. Because the investigator and participant knew
how many capsules were ingested, they were not blinded
to the dose received. The PMO was purchased from the
manufacturer and all capsules were from the same lot
number. They received their first dose of PMO and then
were sent home where they continued to ingest their
assigned dose of PMO daily for 1 week (180 mg once,
twice, or thrice daily). The PMO was taken with the appropriate meal (breakfast; breakfast and dinner; breakfast, lunch, and dinner). They recorded the daily intake
of PMO capsules and any adverse events (e.g., heartburn
and gastroesophageal reflux symptoms). During this
time, they again kept the pain and stooling diary and
collected a stool sample during days 6 to 7 of PMO ingestion. The stool sample, PMO pill container, and pain and
stool diary were returned via courier. Stool samples were
stored at −80°C until further processing.

Microbiome characterization
DNA extraction and sequencing
Microbial DNA was extracted from the stool samples
using the MoBio PowerSoil DNA Isolation kit (Qiagen,
Hilden, Germany) following manufacturer recommendations. The 16S rRNA amplicon sequencing was performed
following the standard Illumina sequencing protocol, as
previously described.16 Briefly, the V4 hypervariable region of the 16S rRNA was amplified by polymerase chain
reaction (PCR) using the NEXTFlex V4 Amplicon-Seq Kit
2.0 (Bioo Scientific, Austin, TX) and sequenced on the
Illumina MiSeq (Illumina, San Diego, CA) platform, yielding 2 × 250 bp paired-end reads (median reads per sample = 46,272). Two negative controls (no template PCR
controls) also were sequenced along with the samples to
monitor the potential background noise (both negative
controls had fewer than 500 reads post-quality filtering
and were excluded from further analysis).

Sequence processing
The Illumina-sequenced paired-end fastq files (i.e., raw
sequences) were demultiplexed (by sample) using the
Illumina MiSeq Reporter analysis software. Primers were
removed using cutadapt.17 The sequence data then were
imported into QIIME 2 (version 2019.10) for processing.18
Denoising and filtering of the sequences were completed
using the DADA2 (version 1.16) pipeline.19 Any features
(i.e., the products of DADA2 denoising) with less than
32 nucleotides length were filtered out of the sequence
table. Chimeric sequences were removed using vsearch
(version 2.7.0).20 Sequences were clustered de novo into
operational taxonomic units (OTUs) at 97% identity using
the QIIME 2-VSEARCH plugin. Taxonomy was assigned
to the sequences using VSEARCH against the SILVA (version 13.2) reference database.21 Any unassigned and nonbacterial sequences (e.g., archaea, chloroplast-derived,
and mitochondrial, etc.) were removed from the data before proceeding with analysis.

Sequence analysis
The quality-filtered feature (sequence) table, taxonomy
table, representative sequences file, and tree file generated
using the QIIME2 pipeline were imported into the phyloseq R-package (version 1.32.0) for subsequent analysis.22
We performed microbiome analyses in a rarefied (i.e.,
subsampled without replacement) read count table where
the samples were rarefied at 9643 reads (the lowest read
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depth in the dataset) to account for differing read depths
across samples.23

with abundance/edges that remained after removing the
lowest 0, 0.1, and 0.2 quantiles.

Taxonomic profiling and diversity analysis

Statistical analysis

We calculated the relative abundance of bacterial taxa
across samples at the phylum, family, genus, and OTU
levels. Alpha diversity, which measures the richness and
evenness of the microbial community in a sample, was
calculated using the Shannon and Simpson indices. Beta
diversity, which measures the similarity (or dissimilarity) of the microbial community composition between
samples, was characterized using the Bray-Curtis index.
Additionally, beta diversity was characterized by the
Aitchison distance,24 which accounts for the compositional nature of microbiome data, following the centered
log-ratio transformation of the read counts.25 Principal coordinate analysis (PCoA) and principal component analysis (PCA) plots were used for visualization of Bray-Curtis
and Aitchison distance data, respectively.

Overall differences in continuous variables between
groups were compared using the Kruskal-Wallis test.
Differences in categorical variables between groups were
compared using chi-square or Fischer’s exact test as appropriate. Average pain severity and frequency per day
were calculated as the average of all pain assessments.
Differences in alpha diversity between and among
groups were detected using the Wilcoxon rank sum test
(two groups) or Kruskal-Wallis test followed by Dunn’s
test (more than two groups). We also performed 1000
bootstraps to calculate the variance of alpha diversity
metrics in baseline and post-PMO samples followed by a
Wilcoxon rank sum test to identify the significance of differences in variances.29 Pearson’s correlation analysis was
performed to investigate the association of continuous demographic variables (age, height, and body mass index of
the participants) with alpha diversity (Shannon index) of
the bacterial microbiome in baseline and post-PMO samples, whereas the Wilcoxon rank sum or Kruskal-Wallis
test was used to assess the alpha diversity by categorical
variables (sex, race, and ethnicity of the participants).
Differences in beta diversity by treatment group (baseline and post-PMO) and PMO dose (180, 360, and 540 mg)
were detected using the permutational multivariate analysis of variance (PERMANOVA)30 test (Adonis function
with 999 permutations in the vegan R-package31). Firstly,
PERMANOVA was performed with an unblocked single
variable design (model 1 example: adonis (bray.dist ~
treatment group, permutations = 999). Second, we included a factor in the model to detect if the PERMANOVA
result differs from that of the unblocked single variable
design (model 2 example: adonis (bray.dist ~ treatment
group*sex, permutations = 999). Finally, we specified the
strata to test whether or not beta diversity by treatment
group differs while controlling for a factor (model 3 example: adonis (bray.dist ~ treatment group, strata = sex, permutations = 999). Based on the results from the model 2,
we tested whether beta diversity differs by PMO treatment
while controlling for sex, ethnicity, and race.
To determine whether demographics/clinical variables
influenced the microbial community composition observed in our samples, we performed PERMANOVA of the
Bray-Curtis dissimilarity indices (baseline and post-PMO).
We tested the effects of gender (male and female), ethnicity (Hispanic and non-Hispanic), and race (Black, White,
and others) on the microbiome composition in baseline
and post-PMO groups separately. We also performed a

Enterotypes classification
The classification of enterotypes to the taxonomic profiles generated from our samples was performed using
the webserver https://enterotypes.org/. Enterotype (clusters of individuals with similar microbiome composition) assignments were based on the classifier trained on
stool samples from the Human Microbiome Project and
MetaHIT studies.26,27

Bacterial network analysis
The genus level abundance table first was normalized
within each sample to the sum of all counts to get the relative abundance. The relative abundances of each genus
then were transformed into 10 quantiles across all samples.
The subject-genus tuples with their respective quantiles
then were imported into Cytoscape 3.8.2.28 The subjects
and genera were interpreted as nodes and the quantiles
as weights of the connecting edges. Additional statistical
information about the genera discriminatory power between the pre- and post-PMO samples (Wilcoxon p value)
was imported into Cytoscape. In Cytoscape, the “Edge-
weighted Spring Embedded Layout” algorithm with the
quantiles as weights was used to generate network layouts
for various slices of nodes/edges combinations. We included the network generated using only genera that were
present in at least five samples, had a Wilcoxon p less than
or equal to 0.05 between pre- and post-PMO samples, and
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homogeneity test of the group dispersion (betadisper
function in vegan) to determine the effect of sample dispersion (variance) on a significant PERMANOVA result.
Microbiome differential abundance analysis was performed using the traditional Wilcoxon rank sum test or
Kruskal-Wallis test. We also used the R package analysis of
variance (ANOVA)-Like Differential Expression version 2
(ALDEx2), which takes into account sample variation and
compositional nature of microbiome data for differential (relative) abundance analysis.32 Benjamini-Hochberg
correction was applied to the control false-discovery rate
(FDR) for multiple hypotheses testing. A p value less than
0.05 was considered statistically significant.

RESULTS
Participant demographics and clinical
characteristics
There was a statistically, but not clinically, significant difference in mean age between the three PMO dose groups
(Table 1). There were no differences among the groups in
the proportion of girls, body mass index, race, or ethnicity.
No differences were noted among the dose groups in
mean abdominal pain severity, number of abdominal pain
episodes per day, or number of stools per day at baseline,
or while taking PMO. When assessing the cohort (n = 30),
T A B L E 1 Participant demographics
and pain/stooling data

Peppermint Oil Dose Group
180 mg
n = 10
Age (years)

a

11.5 ± 0.7

360 mg
n = 10

540 mg
n = 10

p Value

11.4 ± 1.0

10.2 ± 1.3

0.03

Female

8 (80%)

7 (70%)

6 (60%)

0.62

Body mass index

24.0 ± 5.3

21.4 ± 5.0

22.7 ± 4.9

0.42

White

5

4

4

Black

5

5

5

Asian

0

1

0

Native American

0

0

1

Hispanic

4

4

4

Non-Hispanic

6

6

6

Baseline

1.3 ± 1.4

2.2 ± 2.5

1.6 ± 1.0

0.38c

Post-treatment

0.4 ± 0.5

0.5 ± 0.5

1.4 ± 2.6

0.81d

p value

0.21b

0.20

0.88

0.15e

Baseline

1.5 ± 1.3

1.8 ± 1.2

2.8 ± 1.7

0.13c

Post-treatment

0.8 ± 0.8

0.7 ± 0.7

1.2 ± 1.7

0.90d

p value

0.18b

0.16

0.04

0.004e

Baseline

1.0 ± 0.6

1.2 ± 0.6

1.0 ± 0.5

0.66c

Post-treatment

0.8 ± 0.5

0.7 ± 0.4

0.7 ± 0.3

0.89d

0.26

0.24

0.05e

Race

0.96

Ethnicity

1.00

Number of pain episodes
per day

Pain severity 0–10

Number of stools per day

p value

b

0.36

Note: Bold = significant.
Abbreviation: PMO, peppermint oil.
a

Mean ± SD.

b

p value for rank test baseline vs PMO.

c

p value for Kruskal-Wallis test for difference at baseline among groups.

d

p value for Kruskal-Wallis test for difference after PMO administration among groups.

e

p value for rank test for difference between Baseline and PMO administration for participants as a whole
(n = 30).
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mean pain severity was greater during the baseline period
than during PMO treatment (p = 0.004) with the 540 mg
dose group showing a significant decrease in pain severity
(p = 0.04). No differences among dose groups were noted
regarding the number of pain episodes. The number of
stools passed per day for the cohort (n = 30) tended to
be less during the PMO treatment period (p = 0.05). No
adverse events were noted during the study related to administration of PMO. Percent compliance with PMO ingestion did not differ among groups (92 ± 16%, 87 ± 14%,
and 91 ± 7% for dosing groups 180, 360, and 540, respectively; p = 0.30).

Microbial alpha diversity
We found no significant difference (Wilcoxon rank sum
test p > 0.05) in the Shannon diversity (Figure 1a) or
Simpson diversity (Figure 1b) metrics between baseline
and post-PMO samples. However, the variance of diversity
metrics in the baseline samples was significantly greater
than the post-PMO samples (p < 0.001) with both diversity estimators (Figure 1c,d). Alpha diversity was not associated with age, height, or body mass index (Figure S1) or
with sex, race, or ethnicity of the participants (Figure S2).
There was a decreasing trend in alpha diversity in the
540 mg PMO dosing group compared with the 180 and
360 mg groups (for both Shannon and Simpson indexes;
Figure 2a,b), but the values did not achieve statistical

F I G U R E 1 Estimators of microbial
alpha diversity in baseline and PMO
dose groups. Box plots showing Shannon
diversity index (a), Simpson diversity
index (b), variance in Shannon diversity
index (c), and variance in Simpson
diversity index (d) between baseline and
post-PMO samples. The p values between
baseline and post-PMO samples were
calculated using Wilcoxon rank sum test.
The variance of diversity in the baseline
samples was significantly greater than
that in the post-PMO samples (1000
bootstraps followed by a Wilcoxon rank
sum test p < 0.05) for both Shannon
(c) and Simpson (d) indices. PMO,
peppermint oil
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significance after FDR correction. There was no difference
in the diversity by either metric comparing baseline and
PMO results (Figure 2a,b).

Microbial beta diversity
The PCoA ordinations using the Bray-Curtis dissimilarity index revealed no significant difference (Adonis p >
0.05) in bacterial composition between baseline and post-
PMO samples as well as between the PMO dose groups
(Figure 3). The overall heterogeneity in community composition across samples at baseline was relatively higher
(with respect to the median profile), but not statistically
significant (Wilcoxon rank sum test p > 0.05), from the
post-PMO samples (Figure 3b). Like the Bray-Curtis result, PCA of the Aitchison distance using centered log-
ratio transformed data also found no significant difference
(Adonis p > 0.05) in the community composition between
baseline and post-PMO samples (Figure S3).

Demographics variables influencing the
microbial community
We found only one categorical variable (ethnicity) that
seemed to be related to the microbial community composition at baseline (Adonis p < 0.05) via univariate analysis
(Table S1). However, the homogeneity test of dispersion

1042

|

  

THAPA et al.

F I G U R E 2 Alpha diversity among PMO dose groups. Box plots of Shannon (a) and Simpson (b) diversity indices plotted among the
PMO dose groups. The p values were calculated using pairwise Wilcoxon test. p.adj = adjusted p value after false discovery rate (FDR)
correction. PMO, peppermint oil

suggested that the difference could potentially be because
of sample dispersion (Betadisper, p < 0.05). Additionally,
the effect of ethnicity on the community composition was
not significant via multivariate analysis (see Table S1 for
details).
Because we did not detect any significant difference
in the microbial community composition (beta diversity)
of our samples stratified by treatment groups with the reported race, ethnicity, and sex of the children, we did not
expect demographics to be a confounder when identifying
taxa specific to baseline and post-PMO samples. Thus, demographics were not used in identifying taxa.

Microbial taxon abundance
Both baseline and post-PMO gut microbiome were
dominated by two bacterial phyla, Firmicutes (mean
relative abundance across baseline samples = 47%,
post-PMO = 46%) and Bacteroidetes (baseline = 43%,
post-PMO = 46%; Figure 4a). The major bacterial families reported were Bacteroidaceae (baseline = 27%,
post-PMO = 30%), Lachnospiraceae (baseline = 21%,
post-PMO = 18%), Ruminococcaceae (baseline = 19%,
post-PMO = 18%), Prevotellaceae (baseline = 10%, post-
PMO = 8%), and Rikenellaceae (baseline = 4%, post-
PMO = 5%; Figure 4b). The genera Bacteroides (baseline
= 27%, post-PMO = 30%), Prevotella 9 (baseline = 8%,

post-PMO = 7%), Bifidobacterium (baseline = 5%, post-
PMO = 4%), Faecalibacterium (baseline = 5%, post-PMO
= 5%), Alistipes (baseline = 4%, post-PMO = 5%), and
Blautia (baseline = 3%, post-PMO = 3%) were dominant in the participants before and after PMO treatment
(Figure 4c).
We found no differentially abundant major taxa (at the
phylum, family, or genus levels) between baseline and post-
PMO samples using the traditional Wilcoxon rank sum test
(all FDR-corrected p values > 0.05), except a very low abundant family, Coriobacteriaceae (baseline = 0.08%, post-PMO
= 0.22%; p = 0.002; Figure 4d) and the genus Collinsella
(baseline = 0.08%, post-PMO = 0.22%; p = 0.007; Figure 4e)
belonging to the family Coriobacteriaceae. Three OTUs were
differently abundant before and after PMO treatment. They
were otu65, belonging to the genus Collinsella (baseline =
0.1%, post-PMO = 0.2%; p = 0.004); otu92, belonging to the
genus Adlercreutzia (baseline = 0.04%, post-PMO = 0.01%;
p = 0.023), and otu128, belonging to an unclassified member
of the Prevotellaceae family (baseline = 0.01%, post-PMO =
0.002%; p = 0.023). ALDEx2 also identified the OTU belonging to the genus Collinsella (family: Coriobacteriaceae) as
the only differentially abundant taxon between baseline and
post-PMO samples.
Network analysis of bacterial genera using Cytoscape
showed a clear separation between the pre-  and post-
PMO samples, with few overlaps (Figure 5). The genus
Collinsella was driving the post-PMO clusters, whereas
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F I G U R E 3 Bray-Curtis dissimilarity-
based microbial beta diversity and inter-
individual divergence in baseline and
PMO dose groups. (a) Principal coordinate
analysis (PCoA) plot of the Bray-Curtis
index between the baseline and post-PMO
cohorts. (b) Inter-individual divergence
in the bacterial community composition
across samples in the baseline and post-
PMO cohorts. (c) Bray-Curtis indexbased
PCoA plot of the samples grouped by
baseline and PMO dose groups. (d)
Bray-Curtis indexbased PCoA plot of the
samples grouped by PMO dose groups.
The percentage of variance accounted
for by the first two principal coordinates
(PCo) that explained the largest fractions
of variability in our data are shown in the
axis labels in the PCoA plots. Each point
represents a sample and closeness of the
points indicates high similarity in the
microbial community. The ellipses were
drawn at 95% confidence interval. PMO,
peppermint oil

Adlercreutzia and Prevotellaceae unclassified, among others, were the major drivers in pre-PMO (baseline) samples.
No significant differences among the PMO dose groups
(180, 360, and 540 mg) were found in mean relative abundance of bacteria at the phylum, family, or genus levels
(FDR-corrected Kruskal–Wallis p values > 0.05). Similar
results were obtained with ALDEx2. Firmicutes and
Bacteroidetes represented more than 90% of the total
bacterial community in the dose groups (Table S2). The
Firmicutes/Bacteroidetes ratio was lower in children
who received 540 mg of PMO compared to the 180 and
360 mg dose groups (chi-square test p = 0.04; Figure 6a).
Family level bacterial relative abundance is summarized
in Table S3. Although none of the genera were differently
abundant among the dosing groups, Bacteroides was the
most dominant genus across the groups (mean relative
abundance in 180 mg group = 28%, 360 mg = 22% and
540 mg = 41%), followed by Prevotella and Bifidobacterium
(for details see Table S4).

Enterotypes of the gut microbiome
Based on the variation in relative abundance of the bacterial
taxa, we identified two enterotypes: Bacteroides-enriched
(80%) and Firmicutes-enriched (20%) in our samples
(n = 60). Bray-Curtis dissimilarity-based PCoA analysis of
the enterotypes revealed two separate clusters of samples
in both baseline (Figure S4A) and post-PMO (Figure S4B)
samples. We further found a transition of the enterotypes
(Bacteroides to Firmicutes and vice-versa) from pre- (baseline) to post-PMO treatment in six subjects. Seventeen
percent of the participants whose gut microbiome were
Bacteroides-enriched at baseline transitioned to Firmicutes-
enriched enterotype after PMO treatment, whereas only
one participant with Firmicutes-dominant gut microbiome
at baseline transitioned to Bacteroides-dominant type upon
PMO treatment. A subgroup analysis of the Bacteroides-
dominant samples, after excluding those which transitioned
from one enterotype to another in post-PMO treatment,
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F I G U R E 4 Gut microbiome composition of baseline and post-PMO samples. Stacked bar plots showing the average relative abundance
(%) of 16S V4 rRNA gene sequences assigned to each bacterial phylum (a), family (b), and genus (c). Taxa with less than 1% relative
abundance were grouped together for visualization. A higher taxonomic level is reported if the genus level classification could not be
assigned. Unc = unclassified. Box plots showing differently abundant (FDR-corrected p < 0.05) family (d) and genus (e) levels taxa in
baseline and post-PMO groups. FDR, false discovery rate; PMO, peppermint oil

found no significant differences in diversity and composition by PMO treatment (Figure S5) and dose (Figure S6).

DI S C US S I O N
In the present study, we characterized the gut bacterial
microbiome of children with functional abdominal pain

before and after treatment with different doses of PMO.
Although the composition of the gut microbiome overall
did not differ significantly between baseline (untreated)
and after treatment with PMO, abundance of some bacteria (e.g., Collinsella) differed significantly before and after
PMO treatment. In addition, the Firmicutes/Bacteroidetes
ratio was lower in children who received 540 mg of PMO
compared to the 180 and 360 mg dose groups. The human
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F I G U R E 5 Genus level bacterial network in pre-PMO (baseline) and post-PMO samples. Cytoscape was used to generate the network.
The subjects and genera were interpreted as nodes and the quantiles as weights of the connecting edges. The network included only genera
that were present in at least five samples, had a Wilcoxon p less than or equal to 0.05, and abundance/edges that remained after removing
the lowest 0, 0.1, and 0.2 quantiles. PMO, peppermint oil

gut microbiota is mostly composed of these two phyla
that represent greater than 90% of the total community.27
In addition, network analysis revealed separation between pre-  and post-PMO fecal samples with the genus
Collinsella driving the post-PMO clusters.
We found a lower abundance of Collinsella at baseline
than after PMO treatment. Lower gut levels of Collinsella
have been reported in adult patients with irritable bowel
syndrome (another common functional abdominal pain
disorder) compared to sex- and age-matched control individuals.33 Somewhat in contrast, Collinsella has been implicated in increasing gut permeability (known to occur
in irritable bowel syndrome34) by reducing the expression
of tight junction protein in epithelial cells and inducing
expression of IL-17.35 Thus, the role(s) of Collinsella in
symptom generation in functional abdominal pain disorders, such as functional abdominal pain (FAP) in children
requires further investigation as does whether the potential beneficial effect of PMO in treatment of these pain
disorders relates to the impact of PMO on gut microbiome
composition and/or function.
The majority of evidence suggests that PMO is effective
in the treatment functional disorders, particularly irritable bowel syndrome, although two recent studies question
these findings.2–6,36,37 Generally, its beneficial effect has
been ascribed to its ability to act as an antispasmodic.7
However, PMO contains essential oils which are defined
as volatile secondary metabolites of plants that give the

plant a distinctive smell, taste, or both.8 The main constituent and active ingredient of PMO appears to be menthol,
although it contains a large number (~ 300) of other components.8,38 A number of in vitro studies have described
the ability of PMO to exhibit bactericidal activity.39–43 That
said, comparison among studies is difficult because of,
among other issues, differences in the assay used and the
units used to describe the results.9,41 Hence, there is some
discrepancy as to the extent of the antimicrobial nature of
PMO.8,41
Dysbiosis of the gut microbiome may contribute to the
symptom manifestations of functional GI disorders.44,45
Given the potential bactericidal effect of PMO, we speculated that PMO might also exert its beneficial effects
on functional disorders like irritable bowel syndrome
through alteration of gut microbiome composition. To
our knowledge no other studies have examined the effect
of PMO on the gut microbiome in humans. One study in
adults with dyspeptic symptoms, constipation, and/or diarrhea carried out profiling of commensal bacteria using
polymerase chain reaction DNA analysis; however, PMO
was one of multiple ingredients in the treatment, complicating interpretation.46 Similarly, interpretation of a
study by Giannenas et al. is unclear; they examined the
effect in chickens of a feed additive with high concentrations of menthol (the primary ingredient in PMO) on
fecal Escherichia coli and Lactobacillus acidophilus concentrations as subsequently grown in culture; the additive
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F I G U R E 6 Gut microbiome
composition at baseline and in PMO dose
groups. Phylum (a) and genus (b) levels
bar graphs by PMO dosing groups. Taxa
with less than 3% relative abundance
were grouped together as “Others” for
visualization. Baseline samples are also
included in the plots for comparisons.
PMO, peppermint oil

resulted in higher Lactobacillus counts in the jejunum and
E. coli in the colon.47
Contrary to our hypothesis, we found no dramatic
effect of PMO on the gut microbiome. Our findings of
no significant differences in alpha diversity of the bacterial microbiome between the baseline and post-PMO
samples may be attributed, in part, to the significantly
greater variance in alpha diversity scores in the baseline
samples than in the post-PMO samples. At baseline, the
overall pattern of the microbiome, particularly, a higher
relative abundance of Bacteroides and lower abundance
of Faecalibacterium spp., and Akkermansia spp. suggest
an inflammatory, dysbiotic gut community that fits with
previous descriptions of the gut microbiome in functional disorders, such as irritable bowel syndrome.48,49
Following treatment with PMO there were no changes
in the abundance of Bacteroides or potentially beneficial
bacteria, such as Bifidobacterium spp., Faecalibacterium
spp., and Akkermansia spp.

It is not clear why we saw only a small impact of PMO
on the gut microbiome even at the highest dose in contrast to what is reported in in vitro studies. It is possible
that, in humans, PMO does not impact gut microbiome
composition significantly. The formulation of PMO that
we used is enteric coated to reduce the risk of exacerbating gastroesophageal reflux and is not released solely in
the colon.11 In a study using a similar formulation to ours
that presumably was absorbed primarily in the small intestine, Weerts et al. showed in adults with irritable bowel
syndrome that it improved symptoms.36 In contrast, in
the same study, a PMO formulation released in the colon
was not efficacious.36 These results call into question the
long-standing presumption that PMO exerts its beneficial
effect in the colon. Future studies evaluating the effect of
PMO on the gut microbiome may seek to collect samples
at more proximal sites such as the duodenum or jejunum,
as changes in small bowel (or gastric) microbiome composition may be playing a larger role.

PEPPERMINT OIL EFFECTS ON THE GUT MICROBIOME

It also is possible that there are other mechanisms
by which PMO exhibits its protective effects that do not
necessarily involve changes in the bacterial composition of the gut. For example, Botschuijver et al. using a
rat maternal separation model for irritable bowel syndrome reported that the gut mycobiome of maternally
separated and non-separated rats differed.50 Treatment
of both groups with a combination of PMO and caraway shifted the gut mycobiome composition so that
they were similar after treatment.50 The change in mycobiome composition was associated with a reversal of
visceral hypersensitivity in the maternally separated
rats.50 In contrast, treatment with PMO and caraway
did not lead to a coherent shift in microbiome composition; the change in visceral hypersensitivity was related to the change in yeast but not bacteria.50 PMO has
been described as being capable of inhibiting growth
of yeast.9,50 Given these reports, future human studies
potentially should interrogate the gut mycobiome after
PMO administration.
Limitations of this study are primarily those of small
sample size. Although our sample size was reasonably
robust (30 samples each in the baseline and post-PMO
groups), given the trends in microbial shifts that we identified, a larger sample size will be necessary to capture
these shifts in their full complexity. Use of whole genome
shotgun sequencing, although significantly more expensive than the 16S sequencing used in this study, would
provide greater sequencing depth and precision.
Strengths of the study include the use of a well-
characterized clinical cohort, a trial in which each participant acted as their own control (providing pre- and
post-PMO treatment stool samples), expertise in microbiome studies, and following well-established protocols
derived from the Human Microbiome Project. As noted
above, the impact of PMO on the human microbiome
has yet to be studied in adults, much less in children.
Our findings provide the first benchmark information
about the effect of PMO (and its dosing) on gut bacterial
community and suggest that, at the doses studied, the
clinical benefit of PMO may not be mediated through
changes in gut microbiome composition. The study duration should have been long enough to detect potential
changes in microbiome composition based on previous (in vitro and rodent) studies of the effect of PMO
on gut bacteria.7–9 Further studies using a multi-omics
approach (microbiome, metabolomics, and metaproteomics) may provide new information about how PMO
exerts its beneficial effects in functional disorders and
potentially reveal targets for manipulation for prevention or management of the associated gastrointestinal
symptoms.
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